loading page

Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice
  • Jung-Eun Park ,
Jung-Eun Park
Chungnam National University
Author Profile
Author Profile


Rabies is a viral disease that causes severe neurological manifestations both in humans and mammals. Although inactivated and/or attenuated vaccines have been developed and widely used around the world, there are still concerns with regard to their safety, efficacy, and costs. As demand has grown for a new rabies vaccine, we have developed a new vesicular stomatitis viruses (VSVs) based rabies vaccine that replaces glycoproteins with rabies virus (RABV) glycoprotein (GP), or so-called VSV/RABV-GP. The generation of VSV/RABV-GP was evaluated with GP-specific antibodies and reduced transduction with GP-specific neutralizing antibodies. Mice immunized with VSV/RABV-GP produced higher levels of both IgM and IgG antibodies compared to inactivated RABV. The secretion profiles of IgG1 and IgG2a production suggested that VSV/RAVB-GP induces the T helper cell type-2 immune bias. In addition, VSV/RAVB-GP immunization produced a neutralizing antibody of 103.37 IU/mL. Our results confirm that VSV/RABV-GP could be a new potential vaccination platform for RABV.

Peer review status:UNDER REVIEW

12 Aug 2020Submitted to Transboundary and Emerging Diseases
15 Aug 2020Submission Checks Completed
15 Aug 2020Assigned to Editor
15 Aug 2020Review(s) Completed, Editorial Evaluation Pending
15 Aug 2020Editorial Decision: Revise Major
18 Aug 20201st Revision Received
25 Aug 2020Submission Checks Completed
25 Aug 2020Assigned to Editor
26 Aug 2020Reviewer(s) Assigned